β-Amyloid: Enemy or remedy?

Science Translational Medicine

Volumn 4, Issue 145, 2012, Pages

  Hohlfeld, Reinhard ^a   Wekerle, Hartmut ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN SPECIFIC MONOCLONAL ANTIBODY; AMYLOID BETA PROTEIN VACCINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENCEPHALITIS; HUMAN; MENINGOENCEPHALITIS; MULTIPLE SCLEROSIS; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY;

AMYLOID BETA-PEPTIDES; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION; PARALYSIS; TH1 CELLS; TH17 CELLS;

EID: 84864554992     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004586     Document Type: Short Survey

References (10)

1. I. Benilova, E. Karran, B. De Strooper, The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
2. A. Aguzzi, C. Haass, Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302, 814-818 (2003).
3. B. D. Trapp, K.-A. Nave, Multiple sclerosis: An immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247-269 (2008).
4. J. L. Grant, E. E. B. Ghosn, R. C. Axtell, K. Herges, H. F. Kuipers, N. S. Woodling, K. Andreasson, L. A. Herzenberg, L. A. Herzenberg, L. Steinman, Reversal of paralysis and reduced inflammation from peripheral administration of β-Amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci. Transl. Med. 4, 145ra105 (2012).
5. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, M. Kivipelto, Alzheimer's disease: Clinical trials and drug development. Lancet Neurol. 9, 702-716 (2010).
6. R. B. DeMattos, K. R. Bales, D. J. Cummins, S. M. Paul, D. M. Holtzman, Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (2002).
7. A. Kellner, J. Matschke, C. Bernreuther, H. Moch, I. Ferrer, M. Glatzel, Autoantibodies against β-amyloid are common in Alzheimer's disease and help control plaque burden. Ann. Neurol. 65, 24-31 (2009).
8. S. S. Ousman, B. H. Tomooka, J. M. van Noort, E. F. Wawrousek, K. C. O'Connor, D. A. Hafler, R. A. Sobel, W. H. Robinson, L. Steinman, Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 448, 474-479 (2007).
9. Y. S. Eisele, U. Obermüller, G. Heilbronner, F. Baumann, S. A. Kaeser, H. Wolburg, L. C. Walker, M. Staufenbiel, M. Heikenwalder, M. Jucker, Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis. Science 330, 980-982 (2010).
10. J. A. R. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, R. O. Weller, Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat. Med. 9, 448-452 (2003).